SUBSCRIBE
SUBSCRIBE

Phase 2

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
GW Pharma Surges on Positive Phase II Cannabis-Based Drug Study for Schizophrenia and Some Rare Diseases
September 15, 2015
 · 
2 min read
Drug Development
Celsion Updates Clinical Trial Data and Slashes 20% of Workforce
September 9, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Genentech to Present Data from 15 Oncology Studies at European Cancer Congress
September 8, 2015
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
In Response to Twitter Rumors and Phase II Data, Verastem Stock Plunges
August 27, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Esperion Rockets as Lead Drug ETC-1002 Will Not Require Heart Trial for FDA Approval
August 18, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Genentech’s Atezolizumab Shrank Tumors in Phase II Lung Cancer Trial
August 17, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Avalanche Biotech Goes Back to Drawing Board, Performs More Preclinical Studies on Eye Drug
August 14, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Genentech, AbbVie Confirm Venetoclax Met Primary Endpoint in Phase II Study
August 12, 2015
 · 
3 min read
Drug Development
Bay Area’s XOMA (US) LLC to Cut Jobs and Change Focus in Light of Q2 Filings and Stock Drop
August 7, 2015
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Business
Embattled Vitae Pharma and Boehringer Ingelheim Relationship Takes Another Blow, Drops BACE Inhibitor Program for Alzheimer’s
July 27, 2015
 · 
3 min read
Load More
PRESS RELEASES
Press Releases
Ukko Announces First Participant Dosed in Phase 1/2a Clinical Study Evaluating UKK-0018 for Peanut Allergy Treatment
May 7, 2026
 · 
3 min read
Press Releases
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
May 7, 2026
 · 
12 min read
Press Releases
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
May 7, 2026
 · 
8 min read
Press Releases
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
May 7, 2026
 · 
6 min read
Press Releases
Cardiol Therapeutics’ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
May 7, 2026
 · 
7 min read
Press Releases
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
May 7, 2026
 · 
5 min read
Press Releases
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
May 7, 2026
 · 
15 min read
Press Releases
PHERGain and PHERGain-2 advance therapeutic de-escalation in early HER2-positive breast cancer in selected patients
May 7, 2026
 · 
5 min read
Press Releases
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
 · 
18 min read
Press Releases
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
May 7, 2026
 · 
7 min read
Press Releases
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
May 7, 2026
 · 
1 min read
Press Releases
Bioxodes presents positive final Phase 2a intracerebral hemorrhage results at ESOC affirming breakthrough potential of BIOX-101
May 6, 2026
 · 
5 min read
Press Releases
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
May 6, 2026
 · 
10 min read
Press Releases
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
 · 
14 min read
Press Releases
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
May 6, 2026
 · 
10 min read
Press Releases
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
May 6, 2026
 · 
12 min read
Press Releases
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
May 6, 2026
 · 
11 min read
Press Releases
Immunocore reports first quarter 2026 financial results and provides a business update
May 6, 2026
 · 
22 min read
Press Releases
Spago Nanomedical’s Phase I/IIa study Tumorad-01 Meets a Primary Endpoint and Provides Further Visible Tumor Uptake
May 6, 2026
 · 
3 min read
Press Releases
MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
May 6, 2026
 · 
2 min read
Load More